On November 23, 2020, Deputy Prime Minister of the Republic of Kazakhstan Tugzhanov Yeraly Lukpanovich, accompanied by Akim of Zhambyl region Saparbayev Berdibek Mashbekovich, paid a working visit to RIBSP.

During a visit to the Institute with the participation of the Deputy Head of the Office of the Prime Minister of the Republic of Kazakhstan Smagulov O.M., Vice Minister of Education and Science Daulenov M.M., First Vice Minister of Health Shoranov M.E., First Vice Minister of Industry and Infrastructure Development Uskenbayev K.A., First Vice Minister of Finance Sholpankulov B.Sh., Vice Minister of Information and Social Development Azilkhanov M.A., Vice Minister of Labor and Social Protection Shapkenov S.Zh., Vice Minister of National Economy Alpysov E.A., Deputy Minister of Defense of the Republic of Kazakhstan Tortayev B.K., First Deputy Chairman of the Administrative Police Committee of the Ministry of Internal Affairs of the Republic of Kazakhstan Aubakirov A.A. the construction site for the project “Construction of a biopharmaceutical plant for the production of immunobiological drugs that meet the requirements and standards of good manufacturing practice (GMP) in RIBSP RK” was inspected. The management of the construction company LLP “Ка-Строй ЛТД ” presented the current construction process, and also reported on the procurement process of equipment for the biopharmaceutical plant.

During the visit, Deputy Prime-Minister of the Republic of Kazakhstan Tugzhanov Yeraly Lukpanovich got acquainted with the scientific and production activities of the Institute.

Also, to the attention of the Deputy Prime Minister of the Republic of Kazakhstan Tugzhanov Yeraly Lukpanovich was presented the construction of a 60-apartment building for RIBSP employees. Also, the issues of approving the construction of the 2nd and 3rd houses for RIBSP employees were raised.

During his working visit, Deputy Prime Minister of the Republic of Kazakhstan Tugzhanov E.L. held a working meeting on the main problems of further development of RIBSP and set a number of tasks in solving these problems.

Sorry, this entry is only available in Kazakh and Russian.

On November 6, 2020, Akim of Zhambyl region Saparbayev Berdibek Mashbekovich, accompanied by Akim of Kordai region and other representatives of akimats of Zhambyl region, Kordai district and others, visited RSE RIBSP on a working visit.

During the visit, the process of construction of a 60-apartment building for the employees of the RSE RIBSP was examined. Also, the issues of approving the construction of the 2nd and 3rd houses for employees of the RSE RIBSP were raised.

Further, to the attention of the Akim of Zhambyl region Saparbayev B.M. a construction site for the project “Construction of a biopharmaceutical plant for the production of immunobiological drugs that meet the requirements and standards of Good Manufacturing Practice (GMP) at the RIBSP SC MES RK” was presented. The management of the construction company “Ka-Stroy LTD” presented the current construction process, and also reported on the procurement process of equipment for the biopharmaceutical plant.

During his working visit, Akim of Zhambyl region Saparbayev B.M. set a number of tasks to individual representatives of akimats, construction companies, design companies and RSE RIBSP.

On October 28, 2020, the President of the Republic of Kazakhstan Kassym-Zhomart Tokayev accepted the General Director of the Research Institute for Biological Safety Problems Kunsulu Zakarya.

Kassym-Jomart Tokayev heard information about the main results on the development of a coronavirus infection domestic vaccine.

Kunsulu Zakarya, informed the President that on five platforms on the basis of RIBSP, work to develop COVID-19 vaccines is currently underway. The inactivated vaccine developed by the Institute has been approved by the World Health Organization (WHO) and has passed the first phase of clinical trials. The second phase of clinical trials is currently underway at the National Research Center for Phthisiopulmonology.

Illustrative photo: from open sources

The coronavirus infection subunit domestic second vaccine, which is now on the stage of development, is also approved by the WHO and has successfully passed preclinical studies.

Kunsulu Zakarya reported to the President on the construction of a plant on the territory of the RIBSP for the production of domestic immunobiological preparations with a design capacity of 60 million doses of vaccines per year.

On the meeting, the prospects for the development of RIBSP, increasing the salaries of scientists, attracting young specialists, as well as introducing the concept of “temporary registration of a vaccine” in regulatory legal acts were also discussed. Following the meeting, the President supported the proposal to increase the volume of housing construction for employees of the Institute.

At the end of the meeting, the Head of State gave a number of specific instructions on the development of domestic vaccines. www.akorda.kz

On October 16, 2020, the Minister of Education and Science of the Republic of Kazakhstan Aimagambetov Askhat Kanatovich paid a working visit to the National Scientific Center for Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, designated a clinical base for conducting phase I/II clinical trials of QazCovid-in® – COVID-19 inactivated vaccine.

During the working visit, the Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. a meeting was held with the top management and medical workers of the National Scientific Center for Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, the main and responsible researchers for the phase I/II clinical trials of the QazCovid-in® – COVID-19 inactivated vaccine, carried out within the framework of the scientific and technical program “Development of COVID-19 coronavirus infection vaccine”, which is carried out by the Scientific Research Institute of Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan

During the working meeting, the Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. got acquainted with the course of organization, conduct and the current state of the phase I/II clinical trials of QazCovid-in® – COVID-19 inactivated vaccine.

Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. said that the development of a COVID-19 domestic vaccine is under constant control of the Government of the Republic of Kazakhstan. The scientific and technical program “Development of COVID-19 coronavirus infection vaccine” was approved by the Decree of the Government of the Republic of Kazakhstan. For the successful implementation of this STP, the Ministry of Education and Science of the Republic of Kazakhstan allocated additional funds for the material and technical equipment of the RIBSP.

Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. wished all performers and participants of the phase I/II clinical trials of QazCovid-in® – COVID-19 inactivated vaccine the successful completion of the clinical trial and the earliest possible receipt of an effective vaccine in order to ensure the biological safety of the Republic of Kazakhstan!

On October 16, 2020, the Vice Minister of Education and Science of the Republic of Kazakhstan Daulenov Miras Mukhtarovich paid a working visit to RIBSP.

According to the Program of the working visit, a meeting was held with RIBSP employees.

In his speech, the Vice Minister noted that he was aware of the fact that scientists and employees of RIBSP work on “enthusiasm”, difficult working conditions for workers in the “red zone”, problems related to service housing, insufficient basic funding, salaries of scientists and etc.

Vice-minister Daulenov M.M. separately noted that, according to the results of the assessment, the activities of the team and the leader Zakarya K.D., RIBSP was recognized as one of the most effective among research institutes and centers, where an integral system: science – implementation – production is fully built.

At the end of the meeting, Vice-Minister Daulenov M.M. presented the state medals “Халық алғысы (Halyk algysy)” to the scientists of RIBSP Orynbaev M., Zhugunissov R., Kerimbayev A., Kopeyev S.

After the end of the meeting, Vice-Minister Daulenov M.M. got acquainted with the infrastructure of RIBSP, which includes 47 buildings and premises, among them special attention was paid to the progress of the scientific and technical program “Development of COVID-19 coronavirus infection vaccine”: the process of working with experimental animals in the Bioclinic; the process of keeping animals in isolation wards; the process of preparing laboratory glassware; the production process of biological products in the laboratory of technology of finished forms of biological products; the process of building a biopharmaceutical plant.

During a visit to these units, Director General of RIBSP Zakarya K.D. and the heads of the visited units brought to the attention of the Vice-Minister their functions, achievements and existing problems.

At the end of the meeting with employees and familiarization with the activities of RIBSP, Vice-Minister of Education and Science of the Republic of Kazakhstan M.M.Daulenov left for Almaty to get acquainted with the process of conducting clinical trials at the Republican State Enterprise “National Scientific Center for Phthisiopulmonology” of the Ministry of Health of the Republic of Kazakhstan – a clinical base for conducting phase I/II clinical trials of QazCovid-in® – COVID-19 inactivated vaccine.

Sorry, this entry is only available in Kazakh and Russian.

Sorry, this entry is only available in Russian.

The Research Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan (RIBSP) is recruiting volunteers who will take part in the study of a coronavirus vaccine.

The study will be conducted at the clinical base of the National Scientific Center for Phthisiopulmonology. The age of the volunteers who can take part in the vaccine trial is from 18 to 50 years old, all participants must be in excellent health.

What are the requirements for volunteers:

No history of COVID-19 diagnosis. In addition, in the last 14 days from the start of the study, volunteers should not be in close contact with people who have laboratory-confirmed coronavirus or suspected of being infected. Also, according to the rules of the study, participants should not have chronic infections and any allergic reactions. People with alcohol and drug addiction, mental disorders, serious endocrine and kidney disorders will not be allowed to take part in the tests. Volunteers should not be registered with chronic heart and circulatory system diseases. Pregnant and lactating women will also not be able to participate in the study.

Everyone who is admitted to vaccination must sign a voluntary informed consent, keep a daily self-observation diary and visit a doctor on time for several weeks. Each participant of the study will be provided with insurance.

You can get acquainted with the list of indications and contraindications in more detail after submitting an application. Professor B.M. Khairullin was appointed the main researcher from RIBSP.

Please send preliminary questionnaires to

https://docs.google.com/forms/d/e/1FAIpQLScETOtVoRuKuOBkueiuM077hIRHkf3FpctuA9qibguNi19FUQ/viewform?vc=0&c=0&w=1&flr=0

This questionnaire is intended for the selection of volunteers who are ready to take part in clinical trials of the QazCovid-in® COVID-19 inactivated vaccine.

All information collected using this questionnaire is confidential, protected by the legislation of the Republic of Kazakhstan on the protection of personal data, is not subject to disclosure without your consent, and can only be used for the purpose of conducting clinical trials of the Kazakhstani QazCovid-in® – COVID-19 inactivated vaccine.

Recall that the World Health Organization (WHO) has included the Kazakhstan inactivated coronavirus vaccine in the list of candidate vaccines admitted to clinical trials. The domestic vaccine is now in phase 1/2 of clinical trials.

The Kazakhstan QazCovid-in® – COVID-19 inactivated vaccine is registered by WHO as a candidate vaccine for Phase I and II clinical trials. This was reported on the official website of the WHO. A total of 33 candidate vaccines from 19 countries are in clinical trials

Draft landscape of COVID-19 candidate vaccines